Regulatory News for August 2011

Trophos awarded key US patent covering use of novel cardioprotective compound, TRO40303 Trophos awarded key US patent covering use of novel cardioprotective compound, TRO40303

Trophos SA a clinical stage pharmaceutical company developing innovative therapeutics from discovery to clinical validation for indications with under-served needs in neurology and cardiology, announced that the United States Patent and Trademark Office (USPTO) has granted a patent for the use of their novel mitochondrial pore modulator, TRO40303, for cytoprotection. The patent provides coverage for the use of Trophos’ TRO40303 to reduce the cardiac reperfusion injury that contributes significantly to the morbidity and mortality seen after a heart attack [myocardial infarction (MI)].
26 August, 2011